Fusion Antibodies PLC
LSE:FAB
ROE
Return on Equity
ROE, or Return on Equity, is a key financial ratio that measures a company's profitability. Specifically, it measures how many dollars of profit are generated for each dollar of shareholder's equity. A higher ROE indicates better financial performance and effective use of capital, making it a valuable metric for investors assessing a company's earning potential.
ROE Across Competitors
ROE Comparison
Fusion Antibodies PLC Competitors
| Country | UK |
| Market Cap | 3.6m GBP |
| ROE |
-141%
|
| Country | US |
| Market Cap | 222.3B USD |
| ROE |
13%
|
| Country | US |
| Market Cap | 187B USD |
| ROE |
9%
|
| Country | US |
| Market Cap | 42.8B USD |
| ROE |
23%
|
| Country | CH |
| Market Cap | 38B CHF |
| ROE |
7%
|
| Country | KR |
| Market Cap | 56.3T KRW |
| ROE |
9%
|
| Country | US |
| Market Cap | 40.8B USD |
| ROE |
21%
|
| Country | US |
| Market Cap | 28.4B USD |
| ROE |
21%
|
| Country | US |
| Market Cap | 26.7B USD |
| ROE |
-1 261%
|
| Country | IE |
| Market Cap | 25.1B USD |
| ROE |
7%
|
| Country | FR |
| Market Cap | 19.2B EUR |
| ROE |
8%
|
Profitability Report
View the profitability report to see the full profitability analysis for Fusion Antibodies PLC.
See Also
ROE, or Return on Equity, is a key financial ratio that measures a company's profitability. Specifically, it measures how many dollars of profit are generated for each dollar of shareholder's equity. A higher ROE indicates better financial performance and effective use of capital, making it a valuable metric for investors assessing a company's earning potential.
Based on Fusion Antibodies PLC's most recent financial statements, the company has ROE of -140.9%.
You don't have any saved screeners yet
